Outlook Pulls Bevacizumab BLA As Filing Falls Short
Plans To Submit Revised US Application With FDA In Q3
Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.
